Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma

This study tests a combination of three drugs — camrelizumab (immunotherapy), apatinib (a targeted therapy), and temozolomide (chemotherapy) — as a treatment given before surgery (neoadjuvant) for patients with high-risk acral melanoma. Acral melanoma is a rare skin cancer that occurs on the hands, feet, or under nails and is often harder to treat. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with acral melanoma at stage II or III, confirmed by biopsy - You have not received any prior systemic (whole-body) cancer treatment - Your cancer can be measured on imaging - You are in good general health (ECOG 0–1) **You may NOT be eligible if...** - You have already received chemotherapy, immunotherapy, or targeted therapy for melanoma - You have another active cancer - You are allergic to any of the study drugs - You are pregnant or breastfeeding - You have a serious autoimmune condition Talk to your doctor to see if this trial is right for you.